Physician profile
Benjamin M Kalsmith
NPI 1902925837
$1,661,399.60
in general payments reported to CMS, 2019-2025
55 companies · $313K in 2025
The $313K reported for 2025 was more than what 99% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $255K · 2020: $141K · 2021: $204K · 2022: $199K · 2023: $270K · 2024: $280K · 2025: $313K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $700K · Honoraria: $77K · Travel and Lodging: $37K · Food and Beverage: $28K · Consulting Fee: $20K · Education: $9.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $700,148.83 |
| Honoraria | $77,090.00 |
| Travel and Lodging | $37,353.44 |
| Food and Beverage | $28,484.75 |
| Consulting Fee | $20,225.00 |
| Education | $9.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $310,264.64 | 2019-2025 | Camzyos, Eliquis |
| Lilly USA, LLC | $261,540.88 | 2019-2025 | Jardiance, Zepbound, Mounjaro |
| Novo Nordisk INC | $218,320.78 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $187,997.75 | 2019-2025 | Jardiance |
| Amgen INC. | $171,669.65 | 2019-2025 | Repatha, Repatha |
| Pfizer INC. | $126,179.91 | 2019-2025 | |
| Astrazeneca Pharmaceuticals Lp | $65,325.00 | 2019-2025 | Andexxa, Farxiga, Wainua |
| Scpharmaceuticals INC. | $62,915.96 | 2023-2025 | |
| Esperion Therapeutics, INC. | $62,823.39 | 2020-2025 | Nexletol |
| Lexicon Pharmaceuticals, INC. | $37,600.63 | 2023-2024 | Inpefa |
| Bayer Healthcare Pharmaceuticals INC. | $30,857.19 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $30,234.13 | 2019-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $26,396.40 | 2019-2025 | Lifevest |
| Vifor Pharma, INC. | $12,128.51 | 2019-2023 | Veltassa |
| Alexion Pharmaceuticals, INC. | $9,856.01 | 2021-2022 |
Show all 55 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Pharmaceuticals, INC. | $8,862.36 | 2019 | |
| Sanofi-Aventis U.S. LLC | $8,408.10 | 2019-2024 | |
| Impulse Dynamics (USA) INC. | $7,142.62 | 2022-2025 | Optimizer, Optimizer |
| Alnylam Pharmaceuticals INC. | $6,933.40 | 2020-2025 | Amvuttra, Onpattro |
| Portola Pharmaceuticals, LLC | $5,298.47 | 2019-2020 | |
| Medtronic, INC. | $2,850.76 | 2021-2025 | Symplicity G3, Onyx Frontier |
| Janssen Pharmaceuticals, INC | $1,404.98 | 2019-2024 | Xarelto |
| Merck Sharp & Dohme LLC | $965.32 | 2021-2025 | Verquvo |
| Novo Nordisk As | $785.00 | 2025 | |
| Amarin Pharma, INC. | $678.50 | 2019-2022 | |
| Cvrx, INC. | $499.24 | 2021-2024 | Barostim Neo System |
| Boston Scientific Corporation | $433.83 | 2019-2025 | Wolverine Coronary Cutting Balloon, Lux-Dx Insertable Cardiac Monitor, Watchman Access System |
| Abbott Laboratories | $404.50 | 2020-2025 | Diamondback Coronary, Cardiomems, Nc Trek Neo |
| Actelion Pharmaceuticals US, INC. | $336.55 | 2019-2025 | Opsumit, Uptravi, Opsynvi |
| Janssen Scientific Affairs, LLC | $267.81 | 2021-2022 | |
| Kestra Medical Technology Services, INC. | $233.32 | 2022-2025 | Assure Wcd |
| Heartflow, INC. | $189.95 | 2024-2025 | |
| Bridgebio Pharma, INC. | $183.09 | 2025 | Attruby |
| Edwards Lifesciences Corporation | $177.31 | 2022-2025 | Sapien 3 Ultra Resilia |
| Irhythm Technologies, INC. | $167.74 | 2019-2024 | Zio Xt Patch, Zio Monitor |
| Kiniksa Pharmaceuticals International, Plc | $150.14 | 2024 | Arcalyst |
| Biotronik INC. | $146.99 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $107.61 | 2019-2022 | |
| Atricure, INC. | $96.71 | 2019-2025 | Epi-Sense Guided Coagulation System With Visitrax |
| Osprey Medical INC | $88.61 | 2020 | |
| Azurity Pharmaceuticals, INC. | $67.79 | 2024-2025 | Edarbi |
| Daiichi Sankyo INC. | $54.69 | 2022 | |
| Bard Peripheral Vascular, INC. | $50.00 | 2020 | |
| Bardy Diagnostics, INC. | $42.00 | 2022 | |
| Kiniksa Pharmaceuticals, Ltd. | $40.02 | 2023 | Arcalyst |
| Lundbeck LLC | $36.62 | 2020 | |
| Abiomed | $32.16 | 2023 | Impella |
| Corcept Therapeutics | $26.71 | 2023 | Korlym |
| Inspire Medical Systems, INC. | $22.95 | 2023 | Inspire |
| Cardiovascular Systems INC. | $22.14 | 2022 | |
| Altathera Pharmaceuticals LLC | $17.35 | 2022 | |
| Zoll Respicardia, INC. | $17.04 | 2023 | Remede System |
| G Medical Diagnostic Services, INC. | $16.59 | 2021 | |
| Preventice Services, LLC | $16.18 | 2020 | |
| Medtronic Vascular, INC. | $13.62 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Benjamin Kalsmith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.